Mobile therapeutic attention for treatment-resistant schizophrenia: a prospective multicenter feasibility study in patients, caregivers and clinicians

A. Alonso Solís, E. Grasa, K. Rubinstein, A. Caspi, K. Farkas, Z. Unoka, J. Usall, S. Marco, J. Seppälä, E. Jääskeläinen, C. Almazán, J. Caro Mendivelso, A. Triantafillou, P. Kokkinakis, S. van der Graaf, C. Jewell, J. Berdún, E. Reixac, I. Corripio

Research output: Contribution to journalMeeting AbstractAcademic

Abstract

Background: In the European Union around 5 million people suffer from psychotic disorders, and between 20-30% have treatment resistant schizophrenia (TRS) [1]. Mobile interventions may be effective in preventing relapses, increasing treatment adherence and relieving some of the symptoms of schizophrenia, but mHealth studies have not been performed in TRS samples. Smartphone ownership among people with schizophrenia is relatively high and increasing. Moreover, patients seem to be willing and able to use smartphones to monitor their symptoms and engage in therapeutic interventions [2].

Objectives: We present the 3-month prospective feasibility study results of m-RESIST (www.mresist.eu), a new therapeutic program based on novel technology, using wearable computing solutions and offering high modular and flexible functioning. The aim of this project is to assess acceptability, usability and user experience, satisfaction and empowerment after using the m-RESIST solution

Methods: The sample was composed for 39 TRS patients, 11 caregivers and 8 clinicians. The study was carried out in Gertner Institute (Tel-Aviv, Israel), Semmelweis University (Budapest, Hungary) and Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). Acceptability was measured with an adapted version to TRS patients of TAM questionnaire (7-point Likert scale) [3]. In order to assess user experience, a questionnaire was developed and performed at the start, middle and end of the pilot. Satisfaction and empowerment were measured with CSQ-8 [4] and BUES [5] scales respectively.

Results: Patients’ acceptance of m-RESIST ranged from moderate to high, with a mean score for perceived use and ease of use 5.16 and 5.36, respectively. Patient's satisfaction was generally good, 57% thought that the quality of service was good or excellent, 65% reported having received the services they wanted and 43% thought that the program met their needs. However, 19% did not get the kind of service they wanted and for 38% only few of their needs were met. 78% of the sample reported overall satisfaction with m-RESIST and 70% would use it again. Regarding user experience, patients indicated that m-RESIST facilitates easier and quicker communication with clinicians. Also the feeling of having a clinical team concerned and involved in their wellbeing made patients feel more protected and safe. Caregivers were unanimous about the sense of security and also reported that there was more and better support for patients and a better follow-up. Clinicians reported that the m-RESIST system was easy and intuitive to use and felt that it opened up a new communication pathway with their patients. Out of a possible score of 4, which indicates a high level of empowerment, the result of empowerment in our patients was 2.76. Mean for dropouts was 20%.

Conclusions: The m-RESIST solution was well accepted by patients, caregivers and clinicians in terms of acceptability, usability and satisfaction. These results offer an encouraging starting point concerning mHealth technologies in TRS patients, involving clinicians and caregivers.
Original languageEnglish
Article numberP.095
Pages (from-to)104-105
Number of pages2
JournalEuropean Neuropsychopharmacology
Volume29
Issue numberSuppl. 1
DOIs
Publication statusPublished - 2019
Externally publishedYes
Event31st European College of Neuropsychopharmacology Congress, ECNP 2018 - Barcelona, Spain
Duration: 6 Oct 20189 Oct 2018
Conference number: 31

Fingerprint Dive into the research topics of 'Mobile therapeutic attention for treatment-resistant schizophrenia: a prospective multicenter feasibility study in patients, caregivers and clinicians'. Together they form a unique fingerprint.

Cite this